Hepatology International

Article	Citations
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease	410
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)	190
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?	147
Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	100
Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study	92
Liver injury in remdesivir-treated COVID-19 patients	91
Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis	87
Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis	83
Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases	66
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995–2040	66
Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines	60
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma	59
Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations	59
APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy	58
Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders	58
Liver injury in patients with COVID-19: clinical profiles, CT findings, the correlation of the severity with liver injury	56
Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial	51
Effect of COVID-19 on patients with compensated chronic liver diseases	47
Current perspectives on the tumor microenvironment in hepatocellular carcinoma	47
APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients	45
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?	43
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	43
Comparison of 5% human albumin and normal saline for fluid resuscitation in sepsis induced hypotension among patients with cirrhosis (FRISC study): a randomized controlled trial	41
Spleen stiffness measurement for assessing the response to β-blockers therapy for high-risk esophageal varices patients	41
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort	40

Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL)	40
The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis	38
A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC	38
Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis	37
Immunosuppressive regimens for adult liver transplant recipients in real-life practice: consensus recommendations from an Italian Working Group	36
Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trial	36
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study	34
The role of neutrophils in innate immunity-driven nonalcoholic steatohepatitis: lessons learned and future promise	34
High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B	34
SARS-CoV-2 infection and liver involvement	33
Exosomal miR-199a-5p promotes hepatic lipid accumulation by modulating MST1 expression and fatty acid metabolism	33
Cell cycle regulation in NAFLD: when imbalanced metabolism limits cell division	33
An international multidisciplinary consensus statement on MAFLD and the risk of CVD	33
Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China	33
Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study	31
Gut-liver axis modulation of Panax notoginseng saponins in nonalcoholic fatty liver disease	30
The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention	30
Alterations of the salivary and fecal microbiome in patients with primary sclerosing cholangitis	29
Liver fibrosis scores and coronary atherosclerosis: novel findings in patients with stable coronary artery disease	29
Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial	28
A prognostic model for hepatocellular carcinoma patients based on signature ferroptosis-related genes	28
Development and experimental verification of a prognosis model for cuproptosis-related subtypes in HCC	28
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child–Pugh B cirrhosis	27
Non-alcoholic fatty liver disease association with structural heart, systolic and diastolic dysfunction: a meta-analysis	26
Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study	25
Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study)	25
Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure	24
Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis	24
First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients	24
Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer	24
Reduced hepatic steatosis is associated with higher risk of hepatocellular carcinoma in chronic hepatitis B infection	24
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study	23
Management of primary sclerosing cholangitis and its complications: an algorithmic approach	23
Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China	23
Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy	22
Abstract	22
Chronic hepatitis B: the demise of the ‘inactive carrier’ phase	22
Actual long-term survival in hepatocellular carcinoma patients with microvascular invasion: a multicenter study from China	22
Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice	22
The metabolic profiles and body composition of lean metabolic associated fatty liver disease	21
APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19	21
Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease	21
Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation	21
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan	20
Interleukin-22 in alcoholic hepatitis and beyond	20
Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer	20
Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load	19
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population	19
Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation	19
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	19

A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population	19
Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial	19
Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis	18
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B	18
Management of hepatitis B virus reactivation due to treatment of COVID-19	18
Radiomics analysis of contrast-enhanced CT for staging liver fibrosis: an update for image biomarker	18
Prevalence of nonalcoholic fatty liver disease in mental disorder inpatients in China: an observational study	18
Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease	18
Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B	17
Stereotactic body radiotherapy versus intensity-modulated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis	17
Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies	17
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients	17
Prediction of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt treatment: a cohort study	17
Heat-shock protein 90α is a potential prognostic and predictive biomarker in hepatocellular carcinoma: a large-scale and multicenter study	17
Impact of non-alcoholic fatty liver disease on the risk of sarcopenia: a nationwide multicenter prospective study	16
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	16
Controlled attenuation parameter value and the risk of hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy	16
The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study	16
Silencing of functional p53 attenuates NAFLD by promoting HMGB1-related autophagy induction	16
CRISPR/Cas13-assisted hepatitis B virus covalently closed circular DNA detection	16
Randomised clinical trial: effect of adding branched chain amino acids to exercise and standard-of-care on muscle mass in cirrhotic patients with sarcopenia	15
Increased risk of cancer in patients with primary sclerosing cholangitis	15
Gamma knife radiosurgery versus transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study	15
Partial splenic embolization combined with endoscopic therapies and NSBB decreases the variceal rebleeding rate in cirrhosis patients with hypersplenism: a multicenter randomized controlled trial	15
Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis	15
Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications	15
Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study	15
Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice	15
A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion	15
Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines	15
Implications of liver injury in risk-stratification and management of patients with COVID-19	15
Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib	15
A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis	15
Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure	15
Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease	15
A prognostic model of acute-on-chronic liver failure based on sarcopenia	15
Longitudinal progression of clinical variables associated with graded liver injury in COVID-19 patients	15
Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan	14
Metabolic dysfunction-associated fatty liver disease and liver function markers are associated with Crohn’s disease but not Ulcerative Colitis: a prospective cohort study	14
Regression of portal hypertension: underlying mechanisms and therapeutic strategies	14
Predicting liver cyst severity by mutations in patients with autosomal-dominant polycystic kidney disease	14
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients	14
Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients	14
Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease	14
Novel systemic therapy for hepatocellular carcinoma	13
Comparative accuracy of prognostic models for short-term mortality in acute-on-chronic liver failure patients: CAP-ACLF	13
A novel, bedside, etiology specific prognostic model (Peds-HAV) in hepatitis A induced pediatric acute liver failure	13
The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes	13
Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies	13
Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis	13
Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?	12
Abnormal bile acid-microbiota crosstalk promotes the development of hepatocellular carcinoma	12
S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma	12
Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice	12
Dynamic analysis of serum MMP-7 and its relationship with disease progression in biliary atresia: a multicenter prospective study	12
Identification of blood metabolites linked to the risk of cholelithiasis: a comprehensive Mendelian randomization study	12
Liver injury predicts overall mortality in severe COVID-19: a prospective multicenter study in Brazil	12
Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait	12
Portal vein thrombosis associated with high 14-day and 6-week rebleeding in patients after oesophageal variceal band ligation: a retrospective, multicentre, nested case–control study	11
Application of CRISPR-Cas9 based gene editing to study the pathogenesis of colon and liver cancer using organoids	11
A novel machine learning-based radiomic model for diagnosing high bleeding risk esophageal varices in cirrhotic patients	11
Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis	11
Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt	11
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	11
Models for acute on chronic liver failure development and mortality in a veterans affairs cohort	11
Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images	11
Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma	11
‘First week’ is the crucial period for deciding living donor liver transplantation in patients with acute-on-chronic liver failure	11
Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy	11
Application of machine learning in liver transplantation: a review	11
Sorafenib for advanced hepatocellular carcinoma provides better prognosis after liver transplantation than without liver transplantation	11
Association of MAFLD with end-stage kidney disease: a prospective study of 337,783 UK Biobank participants	11
Countdown on hepatitis B elimination by 2030: the global burden of liver disease related to hepatitis B and association with socioeconomic status	11
Consensus on the secondary prevention of primary liver cancer	10
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma	10
A novel epithelial–mesenchymal transition gene signature for the immune status and prognosis of hepatocellular carcinoma	10
Low platelets: a new and simple prognostic marker for patients with hepatitis E virus-related acute liver failure	10
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study	10
Association between metabolically healthy obesity and non-alcoholic fatty liver disease	10
Low-dose continuous terlipressin infusion is effective and safer than intravenous bolus injections in reducing portal pressure and control of acute variceal bleeding	10

Maternal–fetal outcome in pregnancies complicated with non-cirrhotic portal hypertension: experience from a Tertiary Centre in South India	10
Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank	10
Risk factors and outcomes for acute-on-chronic liver failure in COVID-19: a large multi-center observational cohort study	10
Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B	10